This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-27. Anything still debated is marked as such rather than presented as settled.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
== Arrests == On 13 July 2011, operations chief and one of the founders of the organization, Martin Arzola Ortega, was arrested. On 7 August 2012, it was announced that Ortega's successor, Eliot Alberto Radillo Peza, was captured in Zapopan, Jalisco. At the time of Peza's arrest, it was announced that twelve suspected members of the Jalisco Nueva Generacion cartel, including leaders Martin Arzola and Abundio Mendoza Gaytan, had been arrested since July 2011 on extortion, kidnapping and drug charges. On 9 March 2012, another founder of the organization, Érick Valencia Salazar, alias El 85, was captured by the Mexican Army along with another high-ranking lieutenant in Zapopan, Jalisco. Their apprehensions prompted over a dozen blockades throughout the city. 26 public transportation buses were burned with gasoline and then used to block the city streets. More than 30 assault rifles, grenades, cartridges, and ammunition magazines were confiscated. Felipe Calderón, the president of Mexico, congratulated the Mexican army for the capture of Érick Valencia Salazar. The Matazetas (CJNG) later apologized for the blockades by putting up several banners throughout the Guadalajara metropolitan area. They wrote that the blockades were "only a reaction for messing with their CJNG companion", who reportedly dedicated his work to "maintain tranquility in the state of Jalisco." On 18 March 2012, José Guadalupe Serna Padilla, another ranking lieutenant in the cartel, was captured along with another cartel member as well.
=== Surface energy measurement === In industrial corona and plasma processes, cost-efficient and rapid analytical methods are required for confirming adequate surface functionality on a given substrate. Measuring the surface energy is an indirect method for confirming the presence of surface functional groups without the need for microscopy or spectroscopy, often expensive and demanding tools. Contact angle measurement (goniometry) can be used to find the surface energy of the treated and non-treated surface. Young's relation can be used to find surface energy assuming the simplification of experimental conditions to a three phase equilibrium (i.e. liquid drop applied to flat rigid solid surface in a controlled atmosphere), yielding
In 2000, the chapter on Vitamin C in the North American Dietary Reference Intake was updated to give the Recommended Dietary Allowance (RDA) as 90 milligrams per day for adult men, 75 mg/day for adult women, and setting a tolerable upper intake level (UL) for adults of 2,000 mg/day. The table here shows RDAs for the United States and Canada for children, and for pregnant and lactating women, as well as the ULs for adults. For the European Union, the EFSA set higher recommendations for adults, and also for children: 20 mg/day for ages 1–3, 30 mg/day for ages 4–6, 45 mg/day for ages 7–10, 70 mg/day for ages 11–14, 100 mg/day for males ages 15–17, 90 mg/day for females ages 15–17. For pregnancy 100 mg/day; for lactation 155 mg/day. Cigarette smokers and people exposed to secondhand smoke have lower serum vitamin C levels than nonsmokers. The reasoning is that inhalation of smoke causes oxidative damage, depleting this antioxidant vitamin. The US Institute of Medicine estimated that smokers need 35 mg more vitamin C per day than nonsmokers, but did not formally establish a higher RDA for smokers. The US National Center for Health Statistics conducts biannual National Health and Nutrition Examination Survey (NHANES) to assess the health and nutritional status of adults and children in the United States. Some results are reported as What We Eat In America. The 2013–2014 survey reported that for adults ages 20 years and older, men consumed on average 83.3 mg/d and women 75.1 mg/d. This means that half the women and more than half the men are not consuming the RDA for vitamin C.
=== Approvals === The oral formulations of doxepin are FDATooltip Food and Drug Administration-approved for the treatment of depression and sleep-maintenance insomnia, and its topical formulations are FDA-approved the short-term management for some itchy skin conditions. In Australia and the United Kingdom, the only licensed indications are in the treatment of major depression and pruritus in eczema.
Sources: en.wikipedia.org
McKenna found Ari and Chloe's reunion to be "very emotional" and thought it was obvious that they have "a good relationship". She called Ari "a pretty decent guy" and "smooth" for telling Mac about Chloe and Mia. McKenna thought Mac and Ari's break-up was sad, but also obvious to everyone, writing "We all saw the breakup coming but after everything Mac has done for the Parata's — she even gave them her Porsche as drug collateral — it cuts real deep and it's another heartbreak for Home and Away." She later admonished Ari for his actions, writing "Oh Ari, we expected so much better from you. Ari literally left Mac and moved his old girlfriend in immediately and he's somehow surprised that she can't handle the sight of him?" Digital Spy's Susannah Alexander and Daniel Kilkelly believed the serial "lost a solid couple" in Ari and Mac and that fans of the pair were "upset to see them go their separate ways." After Ari and Mia learned they were expecting a baby, Stephen Downie of TV Week stated "If any couple deserves some happiness, it's Ari and Mia". McKenna later labelled Ari's final storyline "heart wrenching" and his wedding to Mia "bittersweet". Entertainment Daily's Steven Murphy said Ari's death "left viewers distraught" and was "a real shock" to those who had no idea Kipa-Williams was leaving the show. He also wrote "The demise was certainly dramatic. But it left many viewers wondering why Home and Away had killed off one of its most popular characters."
==== Detoxification and drug metabolism ==== Enzymes such as CYP3A4, along with the antiporter activities, are also instrumental in the intestine's role of drug metabolism in the detoxification of antigens and xenobiotics.
The common krait (Bungarus caeruleus) is often considered to be the most dangerous snake species in India. Its venom consists mostly of powerful neurotoxins which induce muscle paralysis. Clinically, its venom contains presynaptic and postsynaptic neurotoxins. Due to the fact that krait venom contains many presynaptic neurotoxins, patients bitten will often not respond to antivenom because once paralysis has developed it is not reversible. This species causes an estimated 10,000 fatalities per year in India alone. There is a 70–80% mortality rate in cases where there is no possible or poor and ineffective treatment (e.g., no use of mechanical ventilation, low quantities of antivenom, poor management of possible infection). Average venom yield per bite is 10 mg (Brown, 1973), 8 to 20 mg (dry weight) (U.S. Dept. Navy, 1968), and 8 to 12 mg (dry weight) (Minton, 1974). The lethal adult human dose is 2.5 mg. In mice, the LD50 values of its venom are 0.365 mg/kg SC, 0.169 mg/kg IV and 0.089 mg/kg IP.
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.